Literature DB >> 26506855

Response to: 'Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?' by Jones and Barry.

J Stuart Elborn1, Bonnie Ramsey2, Claire Wainwright3, Michael Boyle4.   

Abstract

Entities:  

Keywords:  Cystic Fibrosis

Mesh：

Substances：

Year:  2015        PMID： 26506855     DOI： 10.1136/thoraxjnl-2015-207611

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


× No keyword cloud information.
  2 in total

1.  Factors Predisposing the Response to Lumacaftor/Ivacaftor in People with Cystic Fibrosis.

Authors:  Julie Mésinèle; Manon Ruffin; Loïc Guillot; Pierre-Yves Boëlle; Harriet Corvol
Journal:  J Pers Med       Date:  2022-02-10

2.  Computed Tomographic Changes in Patients with Cystic Fibrosis Treated by Combination Therapy with Lumacaftor and Ivacaftor.

Authors:  François Arnaud; Nathalie Stremler-Le Bel; Martine Reynaud-Gaubert; Julien Mancini; Jean-Yves Gaubert; Guillaume Gorincour
Journal:  J Clin Med       Date:  2021-05-07       Impact factor: 4.241
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.